Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Trends in Cancer Research   Volumes    Volume 1 
Functional single nucleotide polymorphisms of the ABC-transporter ABCG2/BCRP gene
Yasuo Imai, Satomi Tsukahara, Yoshikazu Sugimoto, Junko Mitsuhashi
Pages: 111 - 120
Number of pages: 10
Trends in Cancer Research
Volume 1 

Copyright © 2005 Research Trends. All rights reserved


ABCG2/BCRP confers resistance to cells against anticancer agents such as 7-ethyl-10-hydroxycamptothecin, topotecan, and mitoxantrone. Many single nucleotide polymorphisms (SNPs) of the ABCG2 gene have been reported. Nine (G34A, C376T, C421A, C458T, A616C, T1291C, T1465C, A1768T, G1858A) out of 20 exonic SNPs are nonsynonymous. A splicing variant 944-949 was also reported. Among them, C376T, found in 2-3% of Japanese population, is the most striking one because it substitutes stop codon for Gln-126, resulting in non-functional truncated protein. The second functional SNP is C421A, substituting Lys for Gln-141. C421A ABCG2-transfected mouse fibroblasts showed markedly decreased protein expression and low-level drug resistance compared with wild-type ABCG2-transfected cells when transfectants expressed similar levels of ABCG2 mRNA. C421A was found in 20-30% of Caucasians and 50-60% of Asians, respectively. G34A, substituting Met for Val-12, and 944-949, deleting Ala-315 and Thr-316, were not associated with significant alteration of the protein expression and drug resistance. Functional alteration caused by the other exonic SNPs has not yet been reported. People with the C376T and/or C421A alleles may express low amounts of ABCG2, resulting in alteration of bioavailability and sensitivity to ABCG2-substrate drugs. In this regard, two clinical studies have been reported. One showed the clinical importance of C421A SNP on pharmacokinetics of topoisomerase I inhibitor, but the other did not agree. Further investigation of subjects bearing C376T and/or C421A on the both alleles, that would express less than 20% of the protein of the homozygous wild-type carriers, will be needed to clarify clinical relevance of ABCG2 SNPs.

Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms